Psychedelic Chronicle

Psychedelic Chronicle provides the latest psychedelic news, research findings, informational guides & more from the world of psychedelics.

[Psychedelic Chronicle @PsychedelicCHR]

Choose Ketamine has announced the completion of its seed financing round, with Manifestations Capital and Notley Ventures leading the charge to expand its ketamine therapy platform across the US. #ketamine #ketaminetherapy https://t.co/QLfGMMwgyi

[Psychedelic Chronicle @PsychedelicCHR]

Psychedelic biotech company Biomind Labs Inc. $BMND $BMNDF announced that it has been granted a Pre-Investigational New Drug (Pre-IND) meeting by the U.S. Food and Drug Administration (@US_FDA) for new chemical entity Triptax™.

https://t.co/g0xBrfB1P1

[Psychedelic Chronicle @PsychedelicCHR]

$FLHLF 🍄🍄🍄

[Filament Health @FilamentHealth]

An unusual cauliflower-shaped psilocybin mushroom flush grown at our R&D facility.

[Psychedelic Chronicle @PsychedelicCHR]

Today developmental-stage psychedelic biopharmaceutical firm @SiloPharma $SILO announced it has begun preclinical toxicity study of novel time-released, dosage-controlled ketamine formulation, designated as SP-26, for the treatment of fibromyalgia.

https://t.co/oCjUqwuQ6a

[Psychedelic Chronicle @PsychedelicCHR]

.@NuminusWellness $NUMIF $NUMI recently announced the development of a mushroom tea bag containing psilocybin for use in clinical research with a goal of being used as a treatment for clients in psychedelic-assisted therapy.
https://t.co/gEPiyrwQoG

[Psychedelic Chronicle @PsychedelicCHR]

.@atai_Life Sciences $ATAI recently announced dosing of the first subject in their Phase 1 SAD trial of VLS-01, a form of N, N-dimethyltryptamine (#DMT) for treatment-resistant depression (TRD).

https://t.co/kmAIAmjrEN

[Psychedelic Chronicle @PsychedelicCHR]

Clinical-stage psychedelic biotech @TrypTherapeutic $TRYP $TRYPF filed two new provisional patents strengthening the company’s intellectual property portfolio as they focus on developing psilocybin-based medicines for illnesses with unmet medical needs. https://t.co/imTPSVZRCP

[Psychedelic Chronicle @PsychedelicCHR]

Leading psychedelic biotech company Biomind Labs Inc. $BMND $BMNDF announced completion of dose administration to 30 healthy subjects with Treatment-Resistant Depression in the Phase II clinical trial for novel drug candidate BMND01.

https://t.co/8SnBLKvUIJ

[Psychedelic Chronicle @PsychedelicCHR]

Today @MindsetPharma CEO @JamesLanthier $MSSTF announced they have identified three additional families of highly novel, non-tryptamine, next-generation psychedelic compounds through discovery work that will be known as Families 6, 7, and 8.
https://t.co/0F7Tm9uZWg

[Psychedelic Chronicle @PsychedelicCHR]

New Exclusive Interview with @MindsetPharma CEO @JamesLanthier. Mr. Lanthier discusses Mindset's current position, development plans and what's ahead. $MSE $MSSTF https://t.co/hHDJDIlOUk

[Psychedelic Chronicle @PsychedelicCHR]

@ExistWell Hello Professor Yaden, let us know if you would be interested in doing any further press highlighting the book upon release. We are excited for our pre-order copy.

[Psychedelic Chronicle @PsychedelicCHR]

.@CybinInc announced a clinical milestone as the first ever novel psilocybin analog to enter clinical development, CYB003, began dosing first two patients in Phase 1/2a trial evaluating the deuterated psilocybin analog for major depressive disorder. $CYBN

https://t.co/95PLZDwPmo

[Psychedelic Chronicle @PsychedelicCHR]

One of the largest ketamine clinic operations in the US, @RevitalistCorp $CALM $RVLWF has announced a partnership agreement with @Awakn_LS $AWKN $AWKNF allowing Revitalist to implement the KARE® protocol for patients suffering from Alcohol Use Disorder. https://t.co/4vi1GcdukC

[Psychedelic Chronicle @PsychedelicCHR]

Psychedelic biotech @SmallPharma $DMT $DMTTF recently announced regulatory approval to initiate a U.K. clinical trial assesing the interaction between SSRIs and the lead DMT candidate SPL026 for patients with Major Depressive Disorder (MDD).

https://t.co/zDnJnPR0mw

[Psychedelic Chronicle @PsychedelicCHR]

Short Wave Pharma has announced a Clinical Trial Agreement with @Sheba_Medical as exclusive commercial partner for a phase II study of psilocybin-assisted psychotherapy for the treatment of anorexia nervosa, the first of its kind.

https://t.co/GEPMGiAduX

[Psychedelic Chronicle @PsychedelicCHR]

.@FieldTripHealth & Wellness announced plans to trade on the TSX Venture Exchange under the ticker $FTHW at market open on 8/17 in addition to news of $19.9 Million in private placement financing.

https://t.co/Ook3NWglXC

[Psychedelic Chronicle @PsychedelicCHR]

Psychedelic biotech firm Biomind Labs Inc. $BMND $MNDF announced a former @US_FDA Director as Medical Advisor for Clinical Trials.

Biomind Labs is currently developing pharmaceutical formulations of psychedelic molecules, DMT, 5-MeO-DMT, & mescaline.

https://t.co/MvYjsvxfV4

[Psychedelic Chronicle @PsychedelicCHR]

You can watch the complete interview from @Channel4News on @YouTube

https://t.co/r2QbXJjQVx

[Psychedelic Chronicle @PsychedelicCHR]

Author @MichaelPollan recently spoke with @KrishGM of @Channel4News regarding how psychedelics can be used to cure mental health issues and ‘change your mind’.

“I think there’s a tremendous potential in psychedelics to relieve human suffering.”

[Psychedelic Chronicle @PsychedelicCHR]

Clinical‐stage natural psychedelic drug development company @FilamentHealth (OTCQB: $FLHLF) (NEO: $FH) (FSE: 7QS) today announced participation in #ProjectSolace, the world’s largest medical psilocybin access + data project with @TheraPsil & @Drug_Science

https://t.co/Mn5H2fvtPW